Published in Am J Pathol on February 01, 2002
The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res (2005) 2.71
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. J Immunol (2008) 0.95
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol (2011) 0.80
IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation. Proc Natl Acad Sci U S A (2014) 0.79
microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells. PLoS One (2015) 0.76
Biological response modifiers in cancer. MedGenMed (2006) 0.76
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. Front Immunol (2016) 0.75
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today (1995) 2.74
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol (1999) 1.67
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med (2000) 1.62
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol (2000) 1.56
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest (2000) 1.39
A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother (2000) 1.15
Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice. J Cancer Res Clin Oncol (1984) 1.07
Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol (1999) 1.06
Melanosomal proteins as melanoma-specific immune targets. Melanoma Res (1997) 1.01
Practical suggestions for successful immunoenzyme double-staining experiments. Histochem J (1993) 1.00
Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. In Vitro Cell Dev Biol Anim (1997) 1.00
Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol (1985) 1.00
Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res (1995) 1.00
Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer (2000) 0.99
Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res (1997) 0.96
alpha-melanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology (1999) 0.93
Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Res (1989) 0.92
Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin Immunol (2001) 0.91
Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res (1994) 0.91
Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther (2000) 0.91
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res (1994) 0.89
Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detect Prev (1999) 0.88
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene (2000) 0.85
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer (2000) 0.85
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother (1994) 0.85
Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther (2000) 0.83
Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother (1996) 0.81
Cytokine-mediated modulation of integrin, ICAM-1 and CD44 expression on human uveal melanoma cells in vitro. Melanoma Res (1995) 0.81
Micro-anatomy related antigen expression in melanocytic lesions. J Pathol (2000) 0.79
Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells. Cancer Res (2000) 0.77
Sunscreen, sun protection, and our many failures. Arch Dermatol (2005) 14.52
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med (2004) 3.96
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell (2005) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol (2005) 2.28
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Arch Dermatol (2008) 2.21
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res (2008) 2.19
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Women's dermatologic diseases, health care delivery, and socioeconomic barriers. Arch Dermatol (2006) 1.94
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Sun exposure, sun protection, and vitamin D. JAMA (2005) 1.74
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 1.63
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) (2001) 1.59
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
Common cancer biomarkers. Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer (2010) 1.50
An immunologic portrait of cancer. J Transl Med (2011) 1.50